Hospira Vinorelbine Tartrate10 mg/1 mL Injection Vial

País: Austràlia

Idioma: anglès

Font: Department of Health (Therapeutic Goods Administration)

ingredients actius:

vinorelbine tartrate, Quantity: 13.85 mg/mL (Equivalent: vinorelbine, Qty 10 mg/mL)

Disponible des:

Hospira Australia Pty Ltd

Designació comuna internacional (DCI):

Vinorelbine tartrate

formulario farmacéutico:

Injection

Composición:

Excipient Ingredients: water for injections

Vía de administración:

Intravenous

Unidades en paquete:

1 x 1 mL vial

clase:

Medicine Listed (Export Only)

tipo de receta:

Not scheduled. Not considered by committee

indicaciones terapéuticas:

Vinorelbine is indicated as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced nonsmall cell lung cancer (NSCLC). In patients with stage IV NSCLC, Vinorelbine is indicated as a single agent or in combination with cisplatin. In stage III NSCLC, Vinorelbine is indicated with in combination with cisplatin.

Resumen del producto:

Visual Identification: A clear, colourless to pale yellow solution & free from visible particulates; Container Type: Vial; Container Life Time: 2 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Estat d'Autorització:

Listed (Export Only)

Data d'autorització:

2008-05-05